Press releaseGlobe Newswire
INmune Bio
INMB · NASDAQ
$1.60+$0.06 (+3.90%)TodayMarket closed ·
Prev close $1.54
Latest news
- Press releasePRNewswire
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
- News
Full Transcript: INmune Bio Q2 2026 Earnings Call
- Press releaseGlobe Newswire
INmune Bio to Attend the 2026 Maxim Growth Summit
- Press releaseGlobe Newswire
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
- Press releaseGlobe Newswire
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
- News
INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe
- Press releaseGlobe Newswire
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
- Press releaseGlobe Newswire
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
- Press releaseGlobe Newswire
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
- Press releasePRNewswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
- Press releaseGlobe Newswire
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
- Press releaseBusiness Wire
Biotech Leaders Launch National Alliance to Define the Future of American Innovation
- Press releaseGlobe Newswire
INmune Bio Inc. Announces 2025 Results and Provides Business Update
- News
Earnings Scheduled For March 30, 2026
- Press releaseGlobe Newswire
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
- News
Earnings Scheduled For October 30, 2025
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
- News
Earnings Scheduled For August 7, 2025
- NewsMohd Haider
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?
- NewsVishaal Sanjay
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
- NewsVishaal Sanjay
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
- NewsAvi Kapoor
Crude Oil Moves Lower; Joby Aviation Shares Surge
- NewsAvi Kapoor
Dow Gains Over 100 Points; Chicago PMI Weakens In June
- News
STAT News Biotech Reporter Adam Feuerstein Posts On X "$INMB raised money today with full knowledge of the Alzheimer's study data, per a source familiar with the transaction."
- News
Market-Moving News for June 27th
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Earnings Scheduled For May 8, 2025
- NewsAvi Kapoor
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
- News
10 Health Care Stocks With Whale Alerts In Today's Session
- NewsTim Melvin
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
- Press releaseBusiness Wire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.